In patients with ACS without ST-segment elevation, therapy with clopidogrel and ASA was more efficacious than ASA alone, with an increased risk of major bleeding. A post hoc analysis of patients with PVD showed that there was a reduction in MI favouring clopidogrel plus ASA compared with ASA alone and an increased risk of minor bleeding. The economic analysis found that at a willingness-to-pay threshold of $50,000 per QALY, for patients with a mean age of 60 years at the time of the initial event or PVD diagnosis, treatment options that included clopidogrel were the most cost-effective compared with ASA alone for the secondary prevention of vascular events. In patients with ACS, clopidogrel plus ASA was found to be most cost-effective. For patients with PVD, clopidogrel alone was the most cost-effective. As the mean age of patients with PVD increases, clopidogrel plus ASA becomes most costeffective for patients with PVD as well.